ImmunoPrecise Antibodies Ltd. (HYFT) — Capital Reinvestment Ratio
Latest as of October 2020:
1.62x
ImmunoPrecise Antibodies Ltd. (HYFT) has a Capital Reinvestment Ratio of 1.62x as of October 2020, meaning it reinvests 2% of its operating cash flow ($440.23K) in capital expenditures ($715.21K). See ImmunoPrecise Antibodies Ltd. free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
1.62x
Capex / Operating Cash Flow
Operating Cash Flow
$440.23K
USD
Capital Expenditures
$715.21K
USD
Data as of
Oct 2020
Most recent filing
ImmunoPrecise Antibodies Ltd. Capital Reinvestment Ratio (2016–2016)
This chart tracks ImmunoPrecise Antibodies Ltd.'s Capital Reinvestment Ratio across 1 annual periods.
Annual Capital Reinvestment Ratio for ImmunoPrecise Antibodies Ltd. (2016–2016)
Year-by-year Capital Reinvestment Ratio for ImmunoPrecise Antibodies Ltd. from 2016 to 2016. For live market cap and broader valuation context, see ImmunoPrecise Antibodies Ltd. stock valuation.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2016 | 0.06x | $284.09K | $17.48K | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow